Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | SARS-CoV-2 | Research

Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola

Authors: Cruz S. Sebastião, Manuela Galangue, Celestina Gaston, Rui Van-Dunen, Joltim Quivinja, Emiliana Lunbungululo, Domingos Alfredo, Alberto Sozinho, Alice Teixeira, Eunice Manico, Deodete Machado, António Mateus, Zinga David, Joana Paixão, Zoraima Neto, Jocelyne Neto de Vasconcelos, Joana Morais

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

SARS-CoV-2 emerged in China and spread throughout the world due to its rapid transmission. The exposure rate in the healthy population is unknown, mainly in resource-limited countries. Herein, we estimated the seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among blood donors in Luanda, the capital city of Angola.

Methods

This was a retrospective study conducted with 343 blood donors. Chi-square and logistic regression were calculated to predict the independent variable for SARS-CoV-2 infection and deemed significant when p < 0.05.

Results

Seroprevalence of anti-SARS-CoV-2 was 4.7%. Positivity rates varied to age groups (3.5–14.3%), gender (0–5%), area of residence (3.1–.6%), educational level (5.1–10.2%), occupation (4.4–7.7%), and the blood donor category (2.0–5.1%). Past and recent infections were detected in 3.2% and 1.5%, respectively. Blood donors under the age of 20 years (OR: 4.58, p = 0.241) and from non-urbanized areas (OR: 1.86, p = 0.293) presented a high risk related to infection. The infection was higher in blood group A and lower in blood group O. The risk of SARS-CoV-2 infection has increased from January 2020 (OR: 0.03, p = 0.001) to August 2020 (OR: 0.57, p = 0.426).

Conclusions

We provide an estimate of the exposure of healthy blood donors in Luanda. Also, we detected anti-SARS-CoV-2 in January 2020, indicating that the SARS-CoV-2 could have been imported during the first month of 2020. Further studies should be performed to assess the exposure rate in different groups from Angola.
Literature
1.
2.
go back to reference Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382:1199–207.CrossRefPubMedPubMedCentral Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382:1199–207.CrossRefPubMedPubMedCentral
4.
go back to reference Ministério da Saúde de Angola. Pandemia da COVID-19 em Angola. Boletin informativo 269: 16 de outubro de 2020. 2020;:58–9. Ministério da Saúde de Angola. Pandemia da COVID-19 em Angola. Boletin informativo 269: 16 de outubro de 2020. 2020;:58–9.
6.
go back to reference Jin ZJ, Dong X, Yuan CY, Dong YY, Bin YY, Qin YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy Eur J Allergy Clin Immunol. 2020;75:1730–41.CrossRef Jin ZJ, Dong X, Yuan CY, Dong YY, Bin YY, Qin YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy Eur J Allergy Clin Immunol. 2020;75:1730–41.CrossRef
8.
go back to reference Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.CrossRefPubMed Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.CrossRefPubMed
9.
go back to reference Filho LA, Szwarcwald CL, Mateos S de OG, de Leon ACMP, de Andrade Medronho R, Veloso VG, et al. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil. Rev Saude Publica. 2020;54:1–10. Filho LA, Szwarcwald CL, Mateos S de OG, de Leon ACMP, de Andrade Medronho R, Veloso VG, et al. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil. Rev Saude Publica. 2020;54:1–10.
11.
go back to reference Sebastião CS, Neto Z, Martinez P, Jandondo D, Antonio J, Galangue M, et al. Sociodemographic characteristics and risk factors related to SARS-CoV-2 infection in Luanda, Angola. PLoS One. 2021;16 3 March:1–10. Sebastião CS, Neto Z, Martinez P, Jandondo D, Antonio J, Galangue M, et al. Sociodemographic characteristics and risk factors related to SARS-CoV-2 infection in Luanda, Angola. PLoS One. 2021;16 3 March:1–10.
12.
go back to reference Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of antibodies to sars-cov-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020;180:1776–86.CrossRef Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of antibodies to sars-cov-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020;180:1776–86.CrossRef
16.
go back to reference Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. Blood Transfus. 2021;19:181–9.PubMedPubMedCentral Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. Blood Transfus. 2021;19:181–9.PubMedPubMedCentral
17.
go back to reference Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. Clin Infect Dis. 2021;72:249–53.CrossRefPubMed Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. Clin Infect Dis. 2021;72:249–53.CrossRefPubMed
18.
go back to reference Banjar A, Al-Tawfiq JA, Alruwaily A, Alserehi H, Al-Qunaibet A, Alaswad R, et al. Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early months of the pandemic in Saudi Arabia. Int J Infect Dis. 2021;104 January:452–7.CrossRefPubMedPubMedCentral Banjar A, Al-Tawfiq JA, Alruwaily A, Alserehi H, Al-Qunaibet A, Alaswad R, et al. Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early months of the pandemic in Saudi Arabia. Int J Infect Dis. 2021;104 January:452–7.CrossRefPubMedPubMedCentral
19.
go back to reference Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Eurosurveillance. 2020;25:1–4. Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Eurosurveillance. 2020;25:1–4.
22.
go back to reference Saeed S, Drews SJ, Pambrun C, Yi QL, Osmond L, O’Brien SF. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. Transfusion. 2021;61:862–72.CrossRefPubMedPubMedCentral Saeed S, Drews SJ, Pambrun C, Yi QL, Osmond L, O’Brien SF. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. Transfusion. 2021;61:862–72.CrossRefPubMedPubMedCentral
24.
go back to reference Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. medRxiv. 2020;82 January:79–82. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. medRxiv. 2020;82 January:79–82.
26.
go back to reference Shaw JA, Meiring M, Cummins T, Chegou NN, Claassen C, Du Plessis N, et al. Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. PLoS One. 2021;16 2 February:1–12. Shaw JA, Meiring M, Cummins T, Chegou NN, Claassen C, Du Plessis N, et al. Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. PLoS One. 2021;16 2 February:1–12.
29.
go back to reference Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol. 2020;190:24–7.CrossRefPubMed Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol. 2020;190:24–7.CrossRefPubMed
30.
go back to reference Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://​doi.​org/​10.​1016/​S0140-6736(20)30183-5.
Metadata
Title
Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola
Authors
Cruz S. Sebastião
Manuela Galangue
Celestina Gaston
Rui Van-Dunen
Joltim Quivinja
Emiliana Lunbungululo
Domingos Alfredo
Alberto Sozinho
Alice Teixeira
Eunice Manico
Deodete Machado
António Mateus
Zinga David
Joana Paixão
Zoraima Neto
Jocelyne Neto de Vasconcelos
Joana Morais
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06814-0

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.